Clinical outcomes of systemic lupus erythematosus (SLE) patients undergoing continuous ambulatory peritoneal dialysis (CAPD)  by Siu, G.Y.P. et al.
20th Annual Scientific Meeting
A4 Hong Kong J Nephrol • October 2004 • Vol 6 • No 2
Messenger RNA expression in the urinary sediment of patients with chronic
kidney diseases
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Background: The degree of renal scarring in kidney biopsy is an important
prognostic factor in patients with chronic kidney diseases. We hypothesize that
the gene expression in the urinary sediment reflects the degree of renal damage.
Methods: We studied 29 patients with chronic kidney disease who underwent
kidney biopsy (12 IgA nephropathy, 17 glomerulosclerosis) and 10 healthy
controls. The mRNA expressions of a panel of target genes in urinary sediment
were measured by real time quantitative polymerase chain reaction. The results
were compared to the degree of histologic damage and renal function decline.
Results: There were significant differences in the urinary expression of
TGF-`, MCP-1 and collagen IV between disease groups and controls. Urinary
TGF-` mRNA expression significantly correlated with estimated glomerular
filtration rate (GFR) (r = –0.412, p = 0.029) and the degree of tubulointerstitial
scarring (r = 0.418, p = 0.024). Urinary MCP-1 expression correlated with the
degree of glomerulosclerosis (r = 0.450, p = 0.014) but not tubulointerstitial
scarring. Urinary MCP-1 expressions correlated with its corresponding level
by ELISA (r = 0.650, p < 0.001), but TGF-` expression did not with its ELISA
level. Urinary TGF-` gene expression correlated with its intrarenal expression
in glomeruli (r = 0.701, p < 0.001) and tubulointerstitium (r = 0.573, p =
0.001) by immunohistochemistry, while urinary MCP-1 gene expression
correlated with its glomeruli (r = 0.576, p = 0.001) but not tubulointerstitium
staining. After 12 months, there was a significant inverse correlation between
the rate of renal function decline and urinary expression of CTGF (r = –0.471,
p = 0.010) and collagen I (r = –0.399, p = 0.032), but not TGF-` or MCP-1.
Conclusions: Among the target genes examined, the mRNA expression of
TGF-` in urinary sediment correlated with renal function, the degree of
histologic damage and intrarenal level in patients with chronic kidney diseases.
Measurement of TGF-`mRNA expression in urine may be a useful non-invasive
tool for assessing the severity of renal damage in patients with chronic kidney
diseases.
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Objective: Osteoporosis and osteopenia are frequent complications after renal
transplantation that may significantly impair the quality of life of transplant
recipients. The current study aims to determine the degree of bone mass loss
associated with renal transplantation in a cohort of Chinese patients. Methods:
Thirty-three consecutive renal transplant recipients were prospectively followed-
up for 1 year. Bone mineral densities (BMD) of L2–4 lumbar spines (LS) and
both hips were measured with dual energy X-ray absorptiometry (DXA)
technique at baseline and 6 months later. Results: Immediately post-transplant,
the mean BMD and Z-score for the whole body and LS were 1.056 g/cm 2 and
–0.4, 0.959 g/cm2 and –0.6 respectively. For the right hip, the mean BMD and
Z-score were 0.726 g/cm2 and –0.6 respectively, whereas for the left hip, the
respective BMD and Z-score were 0.734 g/cm2 and –0.6. At 6 months, 30.3%,
36.4% and 30.3% of patients developed a significant drop (based on the center
least significant change) in the whole body, LS and hips BMD respectively.
Diabetes mellitus status and duration of dialysis pre-transplant were not
correlated with a lower baseline BMD in our sample. Whereas the cumulative
steroid dose, as reflected by a history of acute allograft rejection, was associated
with a more significant drop in BMD post-transplant. Conclusions:
Osteoporosis and osteopenia are common among renal transplant recipients.
Significant loss of BMD in the first 6 months occurs in 30–36% of patients and
predominantly affects the LS, whereas the BMD values of both hips remain
unchanged.
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Methods: To evaluate the clinical outcomes and complications of SLE patients
on CAPD, from January 1995 to December 2002, 18 SLE patients undergoing
CAPD for at least 3 months were reviewed, and 36 age- and gender-matched
non-diabetic CAPD patients were randomly selected as the control group.
Results: The 18 SLE patients had a significantly lower pre-dialysis albumin
level (30.4 ( 6.6 g/dL vs 35.4 ( 5.59 g/dL, p < 0.01). The mean hemoglobin
levels of the two groups were similar (8.52 ( 1.78 g/dL for SLE group vs 9.0 (
1.93 g/dL for control group). There was also no difference between the two
groups in terms of units (u) of blood transfused and the number of patients on
erythropoietin (EPO) treatment (2 u/100 patient-month (p-m) in SLE group vs
14 u/100 p-m in control groupp; 39% in SLE group vs 30% in control group
respectively). However, the weekly dose of EPO used was significantly higher
in the SLE group (6,000 U vs 3,818 U, p < 0.01). Regarding the infective
complications, the SLE group had a higher peritonitis rate (5.7 episodes/
100 p-m vs 2.4 episodes/100 p-m, p < 0.05), and the increase in the overall
infection rate was also remarkable (6.67 episodes/100 p-m vs 1.1 episodes/
100 p-m, p < 0.001). However, no difference could be demonstrated concern-
ing the Tenckhoff catheter exit site infection rate (2 episodes/100 p-m vs
1.7 episodes/100 p-m). The number of patients who received a kidney transplant
or who switched over to hemodialysis were similar among the two groups.
Seven patients died during the follow-up period, and the overall mortality rate
was statistically much higher in the SLE group than the control group (27.8%
vs 5.4%, p < 0.05). Conclusions: SLE patients on CAPD have a significantly
lower pre-dialysis serum albumin level and use a greater amount of EPO to
achieve a comparable hemoglobin level than non-SLE-non-diabetic CAPD
patients. They also have a poorer prognosis in terms of infective complications
and mortality.
Efficacy and safety of atorvastatin therapy for hyperlipidemia in renal
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Objective: Hyperlipidemia is common and an important risk f actor for
cardiovascular diseases among renal transplant recipients. The use of statins in
these patients has been limited by concerns of pharmacokinetic interactions
with calcineurin inhibitors and the risk of rhabdomyolysis. The present study
aims to investigate, in a prospective randomized trial, the safety and efficacy of
the HMG-CoA reductase inhibitor, atorvastatin, in de novo renal transplant
patients (< 3 months’ post-transplantation) at increased cardiovascular risk.
Methods: We randomly assigned 41 adults de novo renal transplant patients to
atorvastatin, 10 mg/day (n = 20) or no treatment (n = 21), and followed them
for 6 months. Serum lipoprotein profile, serum creatinine (sCr), creatinine
clearance (CrCl) and liver (ALT) and creatine kinase (CK) were measured at
baseline and at 1, 2, 3 and 6 months. Results: No difference in baseline serum
lipoprotein profile was observed (p > 0.05). At 6 months, total cholesterol in
the atorvastatin and control groups decreased by 23.5% and 10.3% respectively
(p = 0.002); the corresponding changes in low-density lipoprotein cholesterol
were –42.9% and –10.6%, respectively (p < 0.001). No significant changes in
serum high-density lipoprotein cholesterol, triglyceride, or ALT were observed.
CK, CrCl, sCr and cyclosporine dosage did not differ significantly between the
two groups. Atorvastatin was well tolerated with no serious adverse effects or
withdrawals noted during the follow-up. There was no allograft loss, but one
patient in the control group died of fungal pneumonia during the study.
Conclusions: Atorvastatin (10 mg/day) was both an effective and safe treatment
for dyslipidemia in Chinese de novo renal transplant patients.
